Skip to main content

Romidepsin Dosage

Medically reviewed by Drugs.com. Last updated on Aug 16, 2023.

Applies to the following strengths: 10 mg; 5 mg/mL

Usual Adult Dose for Cutaneous T-cell Lymphoma

14 mg/m2 IV over 4 hours on days 1, 8, and 15 of a 28-day cycle; repeat cycle every 28 days provided patient continues to benefit and is tolerating therapy

Uses: For the treatment of cutaneous T-cell Lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) in patients who have received at least 1 prior systemic therapy.

Usual Adult Dose for Peripheral T-cell Lymphoma

14 mg/m2 IV over 4 hours on days 1, 8, and 15 of a 28-day cycle; repeat cycle every 28 days provided patient continues to benefit and is tolerating therapy

Uses: For the treatment of cutaneous T-cell Lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) in patients who have received at least 1 prior systemic therapy.

Renal Dose Adjustments

Use with caution in patients with end stage renal disease (ESRD).

Liver Dose Adjustments

Mild hepatic impairment: No adjustment recommended.
Moderate hepatic impairment (bilirubin greater than 1.5 x upper limit of normal [ULN] to 3 x ULN or less): Reduce dose to 7 mg/m2.
Severe hepatic impairment (bilirubin greater than 3 x ULN): Reduce dose to 5 mg/2.

Dose Adjustments

NONHEMATOLOGIC TOXICITIES (EXCEPT ALOPECIA):


HEMATOLOGIC TOXICITIES:

Precautions

CONTRAINDICATIONS:


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Reconstitution/preparation techniques:

General:

Monitoring:

Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.